 |
|  |
Dec-09-19 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
Nov-12-19 | Initiated |
SunTrust |
Buy |
$25 |
|
Nov-06-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
Oct-01-19 | Initiated |
Stifel |
Buy |
$27 |
|
Aug-09-19 | Initiated |
BTIG Research |
Buy |
$27 |
|
Jul-22-19 | Initiated |
Cantor Fitzgerald |
Overweight |
|
|
Jul-12-19 | Initiated |
Oppenheimer |
Outperform |
$27 |
|
Jun-13-19 | Initiated |
Mizuho |
Buy |
|
|
Jun-07-19 | Initiated |
ROTH Capital |
Neutral |
$20 |
|
May-31-19 | Initiated |
Guggenheim |
Buy |
|
|
May-24-19 | Resumed |
Citigroup |
Buy |
$26 |
|
Mar-28-19 | Initiated |
SVB Leerink |
Outperform |
$20 |
|
Jan-03-19 | Downgrade |
Stephens |
Overweight → Equal-Weight |
|
|
Nov-05-18 | Initiated |
Jefferies |
Buy |
|
|
Aug-01-18 | Initiated |
Citigroup |
Buy |
$20 |
|
Mar-06-18 | Downgrade |
H.C. Wainwright |
Buy → Neutral |
$12 |
|
Dec-18-17 | Initiated |
Piper Jaffray |
Overweight |
$10 |
|
Oct-12-17 | Resumed |
H.C. Wainwright |
Buy |
$7 |
|
Sep-08-17 | Resumed |
Leerink Partners |
Outperform |
$7 |
|
Nov-08-16 | Reiterated |
Wedbush |
Outperform |
$8 → $7 |
|
|
 |
Dec-13-19 02:18PM | Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents |
Dec-11-19 09:41AM | Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks |
Dec-10-19 09:52AM | Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting GlobeNewswire |
09:48AM | Fate (FATE) Announces Encouraging Data on Immunotherapies Zacks |
09:07AM | Company News for Dec 10, 2019 Zacks |
Dec-09-19 04:19PM | Here Are The Winners From The Year's Biggest Hematology Meeting Investor's Business Daily +41.33% |
02:16PM | Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook Benzinga |
11:04AM | Fate Therapeutics' stock rises on early-stage cancer drug data MarketWatch |
Dec-08-19 07:28PM | Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey |
10:39AM | Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy GlobeNewswire |
Dec-07-19 08:40AM | Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs GlobeNewswire |
Dec-02-19 05:49AM | Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment? Simply Wall St. -9.22% |
Nov-27-19 04:01PM | Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire |
Nov-14-19 04:01PM | Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire |
Nov-06-19 09:01AM | Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting GlobeNewswire -14.74% |
Nov-05-19 07:25PM | Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates Zacks |
04:05PM | Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire |
Oct-29-19 04:01PM | Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results GlobeNewswire |
Oct-28-19 07:44PM | Hedge Funds Have Never Been More Bullish On Fate Therapeutics Inc (FATE) Insider Monkey |
Oct-18-19 08:12AM | What Kind Of Shareholder Owns Most Fate Therapeutics, Inc. (NASDAQ:FATE) Stock? Simply Wall St. -7.15% |
05:57AM | Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? Simply Wall St. |
Oct-01-19 01:48PM | Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio Benzinga -6.37% |
Sep-30-19 08:00AM | Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies GlobeNewswire |
Sep-18-19 04:01PM | Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire |
Sep-12-19 07:38AM | The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga -5.11% |
12:53AM | Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire |
Sep-11-19 04:01PM | Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire |
Sep-10-19 11:06AM | Is Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Paid At A Competitive Rate? Simply Wall St. +8.65% |
Sep-04-19 10:02AM | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks |
Sep-03-19 08:01AM | Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy GlobeNewswire |
Aug-29-19 08:00AM | Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference GlobeNewswire |
Aug-14-19 08:00AM | Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells GlobeNewswire |
Aug-09-19 11:50AM | Edited Transcript of FATE earnings conference call or presentation 6-Aug-19 9:00pm GMT Thomson Reuters StreetEvents |
Aug-07-19 12:20PM | Fate Therapeutics, Inc. (FATE) Q2 2019 Earnings Call Transcript Motley Fool -6.51% |
Aug-06-19 06:35PM | Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Zacks |
03:00PM | Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
Jul-31-19 01:48PM | Steven Cohen Charges Into Chiasma GuruFocus.com |
Jul-30-19 04:01PM | Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2019 Financial Results GlobeNewswire |
Jul-29-19 10:34AM | Will Fate Therapeutics (FATE) Report Negative Q2 Earnings? What You Should Know Zacks |
Jul-26-19 09:39AM | Introducing Fate Therapeutics (NASDAQ:FATE), The Stock That Soared 948% In The Last Three Years Simply Wall St. |
Jul-17-19 04:01PM | Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors GlobeNewswire |
Jul-08-19 08:15AM | Are Natural Killer Cells the Next Big Thing in Immunotherapy? Motley Fool |
Jun-19-19 06:02PM | Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey |
Jun-05-19 05:06AM | Edited Transcript of FATE earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents |
May-30-19 04:05PM | Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire |
May-29-19 08:40AM | Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher Zacks |
07:24AM | What You Must Know About Fate Therapeutics, Inc.'s (NASDAQ:FATE) Beta Value Simply Wall St. |
May-07-19 10:41PM | Fate Therapeutics, Inc. (FATE) Q1 2019 Earnings Call Transcript Motley Fool -5.19% |
06:15PM | Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates Zacks |
05:07PM | Fate Therapeutics: 1Q Earnings Snapshot Associated Press |
04:01PM | Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire |
May-03-19 11:23AM | Is Fate Therapeutics Inc (FATE) A Good Stock To Buy? Insider Monkey |
Apr-30-19 04:05PM | Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results GlobeNewswire |
Apr-24-19 08:00AM | Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting GlobeNewswire |
Apr-18-19 08:01AM | Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development GlobeNewswire |
Apr-02-19 08:00AM | Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment GlobeNewswire |
Apr-01-19 08:01AM | Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting GlobeNewswire |
Mar-26-19 12:12PM | What Do Analysts Think About Fate Therapeutics, Inc.s (NASDAQ:FATE) Earnings Trajectory? Simply Wall St. +5.39% |
Mar-18-19 08:00AM | Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors GlobeNewswire |
Mar-11-19 02:05PM | Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT Thomson Reuters StreetEvents |
Mar-06-19 01:19AM | Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript Motley Fool |
Mar-05-19 04:01PM | Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress GlobeNewswire |
03:00PM | Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
Feb-28-19 04:43PM | Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire |
10:43AM | Cronos (CRON) to Report Q4 Earnings: What's in the Cards? Zacks |
Feb-25-19 10:30AM | Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +12.83% |
07:30AM | Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
Feb-22-19 08:00AM | Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire |
Feb-20-19 08:00AM | Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation GlobeNewswire |
Feb-07-19 04:01PM | Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day GlobeNewswire -6.06% |
Feb-06-19 08:37AM | Fate Therapeutics stock up 11% after FDA clears IND application MarketWatch |
08:00AM | Fate Therapeutics Announces FDA Clearance of IND Application for Worlds First Cell Therapy Derived from an Engineered Pluripotent Stem Cell GlobeNewswire |
Jan-22-19 11:52AM | Why Fate Therapeutics, Inc.s (NASDAQ:FATE) CEO Pay Matters To You Simply Wall St. -7.36% |
Dec-19-18 12:04AM | Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up Insider Monkey -6.05% |
Dec-04-18 09:11AM | Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting GlobeNewswire |
Dec-03-18 04:01PM | Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products GlobeNewswire +10.48% |
08:44AM | Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks |
07:40AM | Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences Discovering Underlying Factors of Influence GlobeNewswire |
Nov-30-18 09:30AM | How Healthcare Is Evolving & Sector Stocks To Watch ACCESSWIRE +8.94% |
09:10AM | Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment MarketWatch |
08:00AM | Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy GlobeNewswire |
Nov-28-18 04:22PM | 3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily |
Nov-16-18 10:35AM | What Kind Of Shareholder Appears On The Fate Therapeutics Incs (NASDAQ:FATE) Shareholder Register? Simply Wall St. |
Nov-11-18 05:42PM | Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 GlobeNewswire |
Nov-08-18 04:01PM | Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -10.00% |
Nov-07-18 01:15AM | Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents |
Nov-01-18 06:40PM | Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.23% |
05:35PM | Fate Therapeutics: 3Q Earnings Snapshot Associated Press |
04:01PM | Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire |
09:01AM | Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting GlobeNewswire |
Oct-29-18 04:01PM | Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results GlobeNewswire -7.30% |
Oct-25-18 03:55PM | 3 Healthcare Stocks To Watch On Thursday ACCESSWIRE +17.68% |
Oct-24-18 09:10AM | New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -9.89% |
Oct-04-18 08:00AM | Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations GlobeNewswire |
Oct-03-18 07:00AM | This Biotech Stock Has Quadrupled and Its Top Shareholder Is Still Buying Barrons.com |
Sep-25-18 04:01PM | Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire |
08:00AM | Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire |
Sep-20-18 11:37PM | Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +5.01% |
04:11PM | Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire |
01:32PM | Why You Need To Look At This Factor Before Buying Fate Therapeutics Inc (NASDAQ:FATE) Simply Wall St. |
|
|
|
 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Valamehr Bahram | Chief Development Officer | Oct 15 | Sale | 14.18 | 6,200 | 87,891 | 66,758 | Oct 16 04:06 PM | Wolchko J Scott | President and CEO | Oct 15 | Sale | 14.44 | 21,017 | 303,458 | 353,969 | Oct 16 04:07 PM | TAHL CINDY | General Counsel and Secretary | Oct 15 | Sale | 14.24 | 10,200 | 145,292 | 80,218 | Oct 16 04:05 PM | Shoemaker Daniel D | Chief Scientific Officer | Oct 15 | Sale | 14.29 | 11,800 | 168,593 | 123,791 | Oct 16 04:04 PM | Redmile Group, LLC | Director | Sep 16 | Buy | 17.50 | 857,143 | 15,000,003 | 11,216,809 | Sep 17 04:22 PM | Nashat Amir | Director | Aug 01 | Sale | 22.53 | 30,866 | 695,392 | 7,539 | Aug 02 04:32 PM | Nashat Amir | Director | Jul 31 | Sale | 22.53 | 31,139 | 701,674 | 7,743 | Aug 02 04:32 PM | Nashat Amir | Director | Jul 30 | Sale | 22.51 | 90,175 | 2,029,560 | 7,949 | Jul 30 06:25 PM | Nashat Amir | Director | Jul 29 | Sale | 22.50 | 329 | 7,403 | 8,545 | Jul 30 06:25 PM | Nashat Amir | Director | Jul 26 | Sale | 22.50 | 27,829 | 626,153 | 8,548 | Jul 30 06:25 PM | Nashat Amir | Director | Jul 24 | Sale | 22.51 | 19,866 | 447,098 | 8,732 | Jul 25 06:24 PM | Nashat Amir | Director | Jul 23 | Sale | 22.51 | 62,033 | 1,396,053 | 8,864 | Jul 25 06:24 PM | Nashat Amir | Director | Jul 22 | Sale | 22.52 | 48,704 | 1,097,019 | 9,275 | Jul 22 05:52 PM | Nashat Amir | Director | Jul 19 | Sale | 22.50 | 1,053 | 23,693 | 9,598 | Jul 22 05:52 PM | Nashat Amir | Director | Jul 18 | Sale | 22.50 | 21,409 | 481,795 | 9,605 | Jul 22 05:52 PM | Shoemaker Daniel D | Chief Scientific Officer | Jun 27 | Option Exercise | 2.90 | 12,500 | 36,250 | 148,091 | Jun 28 04:02 PM | Shoemaker Daniel D | Chief Scientific Officer | Jun 27 | Sale | 20.21 | 12,500 | 252,610 | 135,591 | Jun 28 04:02 PM | Wolchko J Scott | President and CEO | May 16 | Option Exercise | 1.63 | 14,335 | 23,366 | 389,216 | May 17 06:27 PM | Wolchko J Scott | President and CEO | May 16 | Sale | 19.37 | 14,335 | 277,684 | 374,881 | May 17 06:27 PM | Wolchko J Scott | President and CEO | Apr 18 | Option Exercise | 1.63 | 11,459 | 18,678 | 381,724 | Apr 19 04:13 PM | Wolchko J Scott | President and CEO | Apr 18 | Sale | 16.01 | 11,459 | 183,509 | 374,881 | Apr 19 04:13 PM | Wolchko J Scott | President and CEO | Apr 17 | Option Exercise | 1.63 | 8,541 | 13,922 | 382,330 | Apr 19 04:13 PM | Wolchko J Scott | President and CEO | Apr 17 | Sale | 16.17 | 8,541 | 138,132 | 374,881 | Apr 19 04:13 PM | Shoemaker Daniel D | Chief Scientific Officer | Mar 28 | Option Exercise | 2.90 | 12,500 | 36,250 | 148,091 | Mar 29 04:01 PM | Shoemaker Daniel D | Chief Scientific Officer | Mar 28 | Sale | 16.94 | 12,500 | 211,703 | 135,591 | Mar 29 04:01 PM | Wolchko J Scott | President and CEO | Mar 21 | Option Exercise | 1.63 | 20,000 | 32,600 | 394,881 | Mar 22 04:01 PM | Wolchko J Scott | President and CEO | Mar 21 | Sale | 17.61 | 20,000 | 352,160 | 374,881 | Mar 22 04:01 PM | TAHL CINDY | General Counsel and Secretary | Mar 01 | Option Exercise | 2.90 | 25,000 | 72,500 | 115,418 | Mar 05 09:00 AM | TAHL CINDY | General Counsel and Secretary | Mar 01 | Sale | 16.15 | 25,000 | 403,698 | 90,418 | Mar 05 09:00 AM | TAHL CINDY | General Counsel and Secretary | Feb 25 | Option Exercise | 2.90 | 25,000 | 72,500 | 115,418 | Feb 27 04:01 PM | TAHL CINDY | General Counsel and Secretary | Feb 25 | Sale | 16.07 | 25,000 | 401,820 | 90,418 | Feb 27 04:01 PM | Nashat Amir | Director | Jan 30 | Sale | 14.16 | 53,017 | 750,959 | 1,473,186 | Feb 01 05:02 PM | Nashat Amir | Director | Jan 29 | Sale | 14.16 | 97,500 | 1,380,795 | 1,526,203 | Jan 31 06:00 PM | Nashat Amir | Director | Jan 28 | Sale | 13.78 | 70,000 | 964,768 | 1,623,703 | Jan 30 04:10 PM | Nashat Amir | Director | Jan 25 | Sale | 14.14 | 90,000 | 1,272,753 | 1,693,703 | Jan 29 04:31 PM | Nashat Amir | Director | Jan 18 | Sale | 16.28 | 39,483 | 642,834 | 1,783,703 | Jan 23 04:32 PM | TAHL CINDY | General Counsel and Secretary | Jan 07 | Option Exercise | 2.27 | 25,000 | 56,673 | 70,418 | Jan 09 04:03 PM | TAHL CINDY | General Counsel and Secretary | Jan 07 | Sale | 16.00 | 25,000 | 400,000 | 45,418 | Jan 09 04:03 PM | Nashat Amir | Director | Dec 20 | Sale | 12.25 | 33,474 | 410,160 | 1,823,186 | Dec 26 04:13 PM | Nashat Amir | Director | Dec 19 | Sale | 13.40 | 91,210 | 1,222,592 | 1,856,660 | Dec 21 04:12 PM |
|
 |
|
 |
|